PharmaCorp Rx Inc.
PCRX.V
TSX
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 288.12% | 280.14% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 288.12% | 280.14% | |||
| Cost of Revenue | 285.87% | 258.55% | |||
| Gross Profit | 291.73% | 322.47% | |||
| SG&A Expenses | -24.96% | 114.30% | |||
| Depreciation & Amortization | 146.04% | 239.02% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 77.36% | 148.45% | |||
| Operating Income | 131.29% | -84.98% | |||
| Income Before Tax | 161.46% | -64.91% | |||
| Income Tax Expenses | -12,850.00% | 400.00% | |||
| Earnings from Continuing Operations | 172.08% | -65.09% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 1,884.62% | 208.33% | |||
| Net Income | 175.81% | -64.33% | |||
| EBIT | 131.29% | -84.98% | |||
| EBITDA | 148.25% | -79.95% | |||
| EPS Basic | 173.02% | 19.23% | |||
| Normalized Basic EPS | 166.67% | 20.41% | |||
| EPS Diluted | 173.02% | 19.23% | |||
| Normalized Diluted EPS | 166.67% | 20.41% | |||
| Average Basic Shares Outstanding | 3.87% | 103.37% | |||
| Average Diluted Shares Outstanding | 3.87% | 103.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||